Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has shared an announcement.
Hansoh Pharmaceutical Group Company Limited announced that its antibody-drug conjugate, HS-20122 for injection, has received Clinical Trial Approval from the National Medical Products Administration of China. This approval allows the company to conduct clinical trials for advanced solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, and colorectal cancer, potentially enhancing its position in the oncology market.
More about Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development and production of innovative drugs, particularly in the field of oncology. The company is engaged in creating advanced therapeutic solutions, including antibody-drug conjugates, to address various types of cancer.
YTD Price Performance: 37.15%
Average Trading Volume: 8,263,262
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$140.7B
See more data about 3692 stock on TipRanks’ Stock Analysis page.